Search

Displaying results 5021 - 5030 of 10000 in total
  1. Drug

    Maclura pomifera pollen

    go.drugbank.com/drugs/DB10988
    Approved

    Maclura pomifera pollen is the pollen of the Maclura pomifera plant. Maclura pomifera pollen is mainly used in allergenic testing.

  2. Drug

    Glutathione disulfide

    go.drugbank.com/drugs/DB03310
    Approved

    A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

  3. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Then, the medium is filtered and separated from the HUCBCs. … While some of the positive results are credited to HUCBCs’ differentiation potential, the growth factors and cytokines these cells secrete are also implicated.

  4. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Lipids promote the fusion of liposomes to cells. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  5. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. … This results in a slight dulling of sensation that can be used to treat premature ejaculation without interfering with normal sexual pleasure or orgasm.

  6. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. … It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

  7. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    The combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while … MB07811 combines a novel thyroid hormone receptor agonist with the Company's novel HepDirect liver targeting prodrug technology.

  8. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. … For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.

  9. Drug

    Iohexol

    go.drugbank.com/drugs/DB01362
    ApprovedInvestigational

    Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

  10. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5 … Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug.[A193506]